Abstract
The goal of acute stroke therapy is to salvage brain tissue by rapid cerebral artery recanalization to improve microcirculation. A major drawback of fibrinolysis is the activation of platelets leading to a high rate of re-occlusion. Antagonists of the platelet GPIIb/IIIa-receptor inhibit the binding of fibrinogen to platelets counteracting secondary thrombus formation. Also, they were shown to suppress thrombembolus formation and to limit lesion development in cerebral ischemia. We review the literature concerning the use of intravenously administered GPIIb/IIIa-receptor antagonists abciximab, eptifibatide and tirofiban for the treatment of patients with acute ischemic brain infarction. In multicenter, prospective, randomized and placebo-controlled trials abciximab had a higher cerebral bleeding risk, while tirofiban did not increase hemorrhage. When combined with fibrinolysis, abciximab and tirofiban were found to improve cerebral artery recanalization and tissue reperfusion resulting in reduced infarct volumes and improved neurological outcome. Thus, GPIIb/IIIareceptor antagonists have a great potential for the treatment of acute stroke.
Keywords: Stroke, fibrinolysis, reperfusion, hemorrhage, receptor polymorphism
Current Vascular Pharmacology
Title: Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Volume: 6 Issue: 1
Author(s): Rudiger J. Seitz and Mario Siebler
Affiliation:
Keywords: Stroke, fibrinolysis, reperfusion, hemorrhage, receptor polymorphism
Abstract: The goal of acute stroke therapy is to salvage brain tissue by rapid cerebral artery recanalization to improve microcirculation. A major drawback of fibrinolysis is the activation of platelets leading to a high rate of re-occlusion. Antagonists of the platelet GPIIb/IIIa-receptor inhibit the binding of fibrinogen to platelets counteracting secondary thrombus formation. Also, they were shown to suppress thrombembolus formation and to limit lesion development in cerebral ischemia. We review the literature concerning the use of intravenously administered GPIIb/IIIa-receptor antagonists abciximab, eptifibatide and tirofiban for the treatment of patients with acute ischemic brain infarction. In multicenter, prospective, randomized and placebo-controlled trials abciximab had a higher cerebral bleeding risk, while tirofiban did not increase hemorrhage. When combined with fibrinolysis, abciximab and tirofiban were found to improve cerebral artery recanalization and tissue reperfusion resulting in reduced infarct volumes and improved neurological outcome. Thus, GPIIb/IIIareceptor antagonists have a great potential for the treatment of acute stroke.
Export Options
About this article
Cite this article as:
Seitz J. Rudiger and Siebler Mario, Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331303
DOI https://dx.doi.org/10.2174/157016108783331303 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modern Perspectives on the Structure, Function and Evolution of the Relaxin-Like Peptides and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry MicroRNA in Skeletal Muscle: Its Crucial Roles in Signal Proteins, Mus cle Fiber Type, and Muscle Protein Synthesis
Current Protein & Peptide Science Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Obesity in China: What are the Causes?
Current Pharmaceutical Design Breath Analysis Using SIFT-MS to Assess Metabolic Status in Patients After Gastro-oesophageal Cancer Surgery- a Pilot Study
Current Analytical Chemistry Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Impact of Alzheimers Disease on the Functional Connectivity of Spontaneous Brain Activity
Current Alzheimer Research How to Prevent Postpartum Relapse to Smoking
Current Pediatric Reviews Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Alpha-1-Antitrypsin Deficiency and Mechanisms of Liver Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry